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LETTERS
Coronavirus 
Antibodies in Bat 
Biologists
To the Editor: Severe acute re-
spiratory syndrome–associated coro-
navirus (SARS-CoV) is a new coro-
navirus that caused an epidemic of 
8,096 cases of SARS and 774 deaths 
during 2002–2003 (1). Attempts are 
ongoing to identify the natural reser-
voir of SARS-CoV. Several horseshoe 
bat species (Rhinolopus spp.) from 
Asia (2,3) and a sample of bats from 
Africa (4) have been found to be in-
fected by and potential reservoirs for 
various SARS-like CoVs and various 
CoVs that are not SARS-like (2–4). 
However, transmission of bat SARS-
CoV from bats to humans has not been 
reported.
During October 2005, we looked 
for serologic evidence of infection 
among bat biologists attending an 
international meeting in the United 
States. After giving informed con-
sent, volunteer biologists completed 
an anonymous survey and provided 
10 mL of blood. Serum samples were 
tested at the Centers for Disease Con-
trol and Prevention (CDC) for an-
tibodies against inactivated human 
SARS-CoV and against recombinant, 
expressed SARS-CoV nucleocapsid 
protein (SARS-CoV N) by enzyme 
immunoassays (EIAs) as described 
(5,6). This study was approved by the 
CDC Institutional Review Board.
Of 350 registered biologists, 90 
(26%) participated. Of participants, 
89% had worked with or studied 
bats in North America, 21% in South 
America, 11% in Africa, 8% in Asia, 
7% in Europe, and 6% in Australia. 
The primary genera studied by par-
ticipants were Myotis (24%), Tadarida 
(13%), and Eptesicus (10%). A total 
of 20 (23%) participants had worked 
with or had contact with horseshoe bat 
species (Rhinolopus spp.). Because 
this genus has 69 species, distributed 
from Australia to Europe, some partic-
ipants who indicated that they worked 
with the Rhinolopus spp. may likely 
have worked with species found out-
side of Asia. Involvement with bats 
most often consisted of capturing or 
handling them in the fi eld (90%), fol-
lowed by capturing or handling them 
in the laboratory (36%). Urine and fe-
ces were encountered most frequently 
(“always” or “most of the time” by 
66%–68% of participants); contact 
with blood, saliva, or tissues and bites 
or scratches reportedly occurred less 
often (“always” or “most of the time” 
by 4%–28% of participants).
The serum samples from all 90 
participants were negative for an-
tibodies against inactivated SARS-
CoV, and samples from all but 1 were 
negative for SARS-CoV N protein. 
The 1 positive sample gave a strong 
signal (optical density 1.08 at 405 nm 
at a 1:400 dilution) by SARS-CoV N 
protein EIA and against SARS-CoV 
N by Western blot but gave no re-
activity against recombinant SARS-
CoV spike protein or inactivated 
SARS-CoV by either EIA or West-
ern blot. Because the N protein has 
a region that is relatively conserved 
among all known coronaviruses (7), 
the antibodies against SARS-CoV N 
protein could have been induced by 
other CoVs. Previous studies have 
demonstrated that SARS-CoV N pro-
tein can cross-react with polyclonal 
antiserum induced by group 1 animal 
CoVs (8). 
To address the possibility that the 
antibodies from this serum sample 
were not specifi c to SARS-CoV, we 
tested it against recombinant N proteins 
of human CoVs, HCoV-229E, HCoV-
OC43, NL63, and HKU-1. The serum 
reacted to all 4 N proteins, by EIA and 
Western blot, at titers of 400–1,600. 
We then tested the sample against 3 
recombinant fragments of the N pro-
tein from each of 3 viruses: SARS-
CoV, HCoV-229E, and HCoV-OC43. 
One of these fragments, N2, contains a 
highly conserved motif (FYYLGTGP) 
that should detect cross-reacting anti-
bodies; the other 2 fragments should 
detect antibodies specifi c to the strain 
or group. The serum reacted to 2 of 
3 fragments from HCoV-OC43 and 
-229E but to only the N2 fragment 
with the conserved motif from SARS-
CoV (Figure), which suggests that the 
antibodies against SARS-CoV N were 
likely induced by a CoV that was not 
SARS-like.
If the antibodies were induced by 
a SARS-like CoV infection, we would 
expect to have also detected antibod-
ies against recombinant S protein (9) 
or recombinant fragments represent-
ing antigenically distinct regions of 
the N protein of SARS-CoV. We did 
not detect either; instead, we detected 
antibodies against the antigenically 
distinct N fragments from group 1 and 
2 human CoVs. Thus, this survey of 
a sample of bat biologists, who were 
exposed primarily to North American 
bats but also to bats from Asia and 
Africa, showed no evidence of SARS-
like CoV infection.
Our survey found no evidence of 
SARS-CoV transmission from bats 
to humans. However, since the con-
clusion of this study, Dominguez et 
al. found coronavirus RNA in bats in 
North America, particularly Eptesi-
cus fuscus and Myotis occultus (10), 2 
species of the genera handled by 25% 
of the participants in our survey. Of 
interest is whether the bat biologists 
who worked with these bats might be 
at risk for infection with group 1 bat 
CoVs. Unfortunately, the high likeli-
hood of infection with human group 1 
CoVs will make it diffi cult to address 
this question. Additional studies of 
bat SARS-CoV infections in a larger 
number of persons who have been in 
contact with the species found to be 
positive for SARS-like CoV are need-
ed before the risk for SARS-like CoV 
transmission from bats to humans can 
be clearly understood.
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Figure. Antibody reactivity to coronavirus (CoV) nucleocapsid (N) protein fragments by 
ELISA. A set of recombinant protein fragments covering the N protein sequence of human 
CoV [HCoV]–OC43, HCoV-229E, and severe acute respiratory syndrome (SARS)–CoV 
were used as antigen; the serum (1:400 dilution) from the participant was tested by ELISA. 
The fragments include the following HCoVs: HCoV-OC43 N1 (aa 1–119), HCoV-OC43 N2 
(aa 120–332), HCoV-OC43 N3 (aa 333–448), HCoV-229E N1 (aa 1–74), HCoV-229E N2 
(aa 75–311), HCoV-229E N3 (aa 312–389), SARS-CoV N1 (aa 1–105), SARS-CoV N2 (aa 
106–324), and SARS-CoV N3 (aa 325–422). The HCoV-OC43, HCoV-229E, and SARS-
CoV fragments were coated at 4 × 10–7 M,  2.5 × 10–3 M, and 8 × 10–8 M, respectively.  The 
N-terminal of the N protein contains a highly conserved motif (FYYLGTGP) found in all 
CoVs (7). This conserved motif is found in HCoV-OC43 N2, HCoV-229E N2, and SARS-
CoV N2 recombinant protein fragments. The sizes of the expressed protein fragments used 
in this study were confi rmed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. 
In addition, the reactivity of each protein fragment was confi rmed by using Western blot 
with the anti-His antibody and the respective convalescent-phase serum. The mean optical 
density (OD) of absorbance at 405 nm (490-nm reference) of duplicate wells is shown. 
Error bars represent the standard deviation of duplicate wells. 
Letters
Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should contain no more than 300 
words and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have one 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.
